In MYCN-amplified NB cells, the half-life of N-Myc is significantly prolonged due to binding and stabilization by Aurora kinase A (Aurora-A; elevated in NB), resulting in increased steady-state ...

Their results are published in Chemical Science. Lead researcher Professor Andrew Wilson explained, "Aurora-A is an incomplete kinase, which means it relies on protein-protein interactions to ...

Image Source: Zacks Investment Research Puma Biotechnology in-licensed global development and commercialization rights for alisertib, an aurora kinase A inhibitor, from Japan’s Takeda in 2022.